Who are Seretide 500 Accuhaler's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Salmeterol/ fluticasone propionate, Salmeterol/fluticasone Diskus, Salmeterol/Fluticasone Capsair®, Extra fine Formoterol/Beclomethasone, FF/VI 100/25 Inhalation Powder NDPI, Formoterol/Fluticasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/seretide-500-accuhaler.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Seretide 500 Accuhaler — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seretide 500 Accuhaler (Seretide 500 Accuhaler) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS). Area: Respiratory / Pulmonology.

marketed Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Seretide 500 Accuhaler (Seretide 500 Accuhaler) — University of Southampton. Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Seretide 500 Accuhaler TARGET	Seretide 500 Accuhaler	University of Southampton	marketed	Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate	Salmeterol/ fluticasone propionate	GlaxoSmithKline	marketed	Long-acting beta-2 agonist / inhaled corticosteroid combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/fluticasone Diskus	Salmeterol/fluticasone Diskus	AstraZeneca	marketed	Long-acting beta-2 agonist/inhaled corticosteroid combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/Fluticasone Capsair®	Salmeterol/Fluticasone Capsair®	Neutec Ar-Ge San ve Tic A.Ş	marketed	Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; glucocorticoid receptor
Extra fine Formoterol/Beclomethasone	Extra fine Formoterol/Beclomethasone	National Institute of Respiratory Diseases, Mexico	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA)	Beta-2 adrenergic receptor; glucocorticoid receptor
FF/VI 100/25 Inhalation Powder NDPI	FF/VI 100/25 Inhalation Powder NDPI	GlaxoSmithKline	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Formoterol/Fluticasone	Formoterol/Fluticasone	Eurofarma Laboratorios S.A.	phase 3	Long-acting beta-2 agonist / Inhaled corticosteroid combination	Beta-2 adrenergic receptor; Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) class)

University of Southampton · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Seretide 500 Accuhaler — Competitive Intelligence Brief. https://druglandscape.com/ci/seretide-500-accuhaler. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab